Cargando…

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment

Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to standard treatments, therefore novel therapies are needed. c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fioramonti, M., Fausti, V., Pantano, F., Iuliani, M., Ribelli, G., Lotti, F., Pignochino, Y., Grignani, G., Santini, D., Tonini, G., Vincenzi, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843583/ https://www.ncbi.nlm.nih.gov/pubmed/29520051 http://dx.doi.org/10.1038/s41598-018-22469-5

Ejemplares similares

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
por: Iuliani, Michele, et al.
Publicado: (2015)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Current and Emerging Biomarkers Predicting Bone Metastasis Development
por: Iuliani, Michele, et al.
Publicado: (2020)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
por: Santini, Daniele, et al.
Publicado: (2015)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer
por: Pantano, Francesco, et al.
Publicado: (2020)

Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
por: Bertani, Francesca R., et al.
Publicado: (2017)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
por: Haider, Marie-Therese, et al.
Publicado: (2015)

Procalcitonin as diagnostic marker of infection in solid tumors patients with fever
por: Vincenzi, B., et al.
Publicado: (2016)

Deregulation of dicer and mir-155 expression in liposarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions
por: Pantano, Francesco, et al.
Publicado: (2021)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
por: Pantano, Francesco, et al.
Publicado: (2022)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Classic Kaposi Sarcoma: to treat or not to treat?
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Phase II Study of Cabozantinib in Patients With Bone Metastasis
por: Choy, Edwin, et al.
Publicado: (2022)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giordano, Giorgia, et al.
Publicado: (2021)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020)

Cetuximab in small bowel adenocarcinoma: a new friend?
por: Santini, D, et al.
Publicado: (2010)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
por: Vincenzi, B, et al.
Publicado: (2006)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1o5gv5tmsh22aehfsnqqc95s7d